Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123
Phase of Trial: Phase III
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Thrombomodulin alfa (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Asahi Kasei
- 12 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2018.
- 12 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Jul 2018.
- 17 Jun 2016 Status changed from not yet recruiting to recruiting.